Vivani Medical (VANI) Corporate presentation summary

Market opportunity and challenges

• Obesity market is rapidly evolving, with over 50 clinical-stage products, mostly injectables or orals, and significant unmet needs in adherence and tolerability.

• Poor medication adherence (<50%) leads to suboptimal outcomes and rapid weight rebound; current options are not ideal for hard-to-reach or convenience-seeking patients.

• GLP-1 market projected to reach $190B by 2035, with obesity-only TAM at $150B and current U.S. penetration at 6%.

Technology and product pipeline

• NanoPortal technology enables ultra long-acting, miniature drug implants for infrequent dosing (6-12 months or longer).

• Lead program NPM-139 is a subdermal semaglutide implant for chronic weight management, with preclinical data showing ~20% sustained weight loss for a year.

• Pipeline includes next-generation incretins, exenatide implants, and veterinary obesity solutions.

Clinical and preclinical results

• LIBERATE-1 first-in-human study met primary objectives: positive safety, tolerability, and device performance.

• Preclinical studies show durable weight loss, stable pharmacokinetics, and 82% reduction in liver fat in obese mice.

• Prototype NPM-139 implant demonstrated sustained delivery and weight loss for a full year in rats.